Seeling et al. [48] demonstrated that treating PTEN-/p16- (p16 is encoded by CDKN2A) cells with palbociclib, a CDK4/6 inhibitor, in combination with rapamycin, an mTOR inhibitor, resulted in a significant reduction in tumor cell viability. The gene discussed is CDKN2A; the disease is neoplasm.